MCM
CEREW

Moore Capital Management’s Cerevel Therapeutics Holdings, Inc. Warrant CEREW Stock Holding History

Moore Capital Management’s Portfolio CEREW Stock Details CEREW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,666
Closed -$94K – 878
2020
Q4 		$94K Buy
+16,666
New +$67.2K ﹤0.01% 510

Other funds holding CEREW

HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
GL
Governors Lane New York $1.2B AUM 26.21% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Moore Capital Management's CEREW Position: Q1 2021 in Review

Moore Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Warrant (CEREW) in Q1 2021, closing a stake of 16,666 shares — an estimated $94K sold.

Moore Capital Management first reported a position in CEREW in Q4 2020 and held it in 1 quarter. The position peaked at $94K in Q4 2020. 29 funds tracked by Wall St. Rank hold CEREW as of Q1 2021.

  • Moore Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Warrant position as of Q1 2021 after selling out during the quarter.
  • Moore Capital Management sold 16,666 Cerevel Therapeutics Holdings, Inc. Warrant shares in Q1 2021, an estimated $94K.
  • Moore Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Warrant in Q4 2020 and held it in 1 quarter.
  • Moore Capital Management's Cerevel Therapeutics Holdings, Inc. Warrant position peaked at $94K in Q4 2020.
  • 29 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Warrant as of Q1 2021.

Based on Moore Capital Management's 13F filing for Q1 2021, filed 17 May 2021.